However, most clinical trials have failed to demonstrate the benefit of EGFR-targeted therapies in gliomas, as approved EGFR therapies have mainly focused on NSCLC EGFR gene alterations that are, however, distinct from those driving gliomagenesis (Lin et al., 2022). This evidence concerns the gene EGFR and glioma.